Showing 81 - 90 of 1,124
Policy makers use reference pricing to curb pharmaceutical expenditures by reducing coverage of expensive branded drugs. In a theoretical analysis we show that the net effect of reference pricing is generally ambiguous when accounting for entry by generic producers. Reference pricing shifts...
Persistent link: https://www.econbiz.de/10014080046
This paper studies the optimal design of a pension system together with publicly-provided individualized financial education. Agents can invest in both a risky and a non risky asset and can either under- or over-estimate the expected return of the risky asset. We show that, under perfect...
Persistent link: https://www.econbiz.de/10013365807
This paper studies empirically the relationship between competition and risk taking in banking markets. We exploit an unique dataset providing information about all bank loans to Norwegian firms over several years. Rather than relying on observed market shares, we use the distance between bank...
Persistent link: https://www.econbiz.de/10014284697
Persistent link: https://www.econbiz.de/10014297070
This paper studies empirically the relationship between competition and risk taking in banking markets. We exploit an unique dataset providing information about all bank loans to Norwegian firms over several years. Rather than relying on observed market shares, we use the distance between bank...
Persistent link: https://www.econbiz.de/10014354215
Persistent link: https://www.econbiz.de/10014477005
This paper analyzes the regulation of payment schemes for health care providers competing in both quality and product differentiation of their services. The regulator uses two instruments: a prospective payment per patient and a cost reimbursement rate. When the regulator can only use a...
Persistent link: https://www.econbiz.de/10005636014
Persistent link: https://www.econbiz.de/10010675343
Persistent link: https://www.econbiz.de/10010703950
This paper analyzes the regulation of payment schemes for health care providers competing in both quality and product differentiation of their services. The regulator uses two instruments: a prospective payment per patient and a cost reimbursement rate. When the regulator can only use a...
Persistent link: https://www.econbiz.de/10008643934